Scientists at the Engelhardt Institute of Molecular Biology (IMB), Russian Academy of Sciences, have developed a highly effective drug against COVID-19. This was announced by the director of the institute, Alexander Makarov, at a meeting with Russian President Vladimir Putin on the development of genetic technologies. RIA News…
According to Academician Makarov, the new drug was created “on the basis of monoclonal antibodies that neutralize coronavirus, including delta and gamma variants.” Monoclonal antibodies produced by immune cells can be obtained for virtually any natural antigen and used to detect or purify it.
Makarov noted that the effectiveness of the new drug has been proven by laboratory tests, including on animals.
On November 13, it became known that the first domestic injectable drug for the treatment of direct-acting coronavirus was registered in Russia. It is called Areplivir and will be admitted to hospitals by the end of 2021. This was announced by the developer company “Promomed”.
Full production and supply of the drug to Russian hospitals will begin in December 2021. It is noted that a multicenter clinical study of the drug led by Academician of the Russian Academy of Sciences Dmitry Pushkar confirmed the effectiveness and safety of the drug when used in hospitals.
According to the head of the Ministry of Health, Mikhail Murashko, no country in the world has a cure for coronavirus. The minister stressed that a drug developed in Russia will be able to interrupt the course of COVID-19 at the initial stage of infection.
In addition, earlier in November it became known that the Russian company Valenta Pharm had created its own drug for coronavirus – innoviron. Experts conducted the second phase of testing the drug back in June; 340 volunteers took part in 13 medical institutions. At the end of October this year, documents were sent to register the development.
According to Nikolay Bespalov, Development Director of RNC Pharma, Valenta Pharm will be able to position innovation as a drug against influenza and ARVI.
Another drug developed in Russia against the coronavirus, Mir-19, is completing the second phase of clinical trials. This was stated by the head of the Federal Medical and Biological Agency (FMBA) Veronika Skvortsova at the X anniversary international scientific and practical conference “Molecular Diagnostics – 2021”.
She recalled that Mir-19 belongs to the group of etiotropic antiviral drugs. It is intended to prevent or treat COVID-19 via inhalation or intranasal administration.
Skvortsova assured that the drug is safe and does not affect the human genome and immunity. At the same time, Mir-19 prevents the most severe forms of coronavirus development.
At the moment, there is a decrease in the incidence of COVID-19 in Russia. This assessment of the development of the coronavirus pandemic was given by the head of Rospotrebnadzor Anna Popova, quoted by TASS.
The dynamics of a decrease in the growth in the number of patients with coronavirus infection is observed in ten Russian regions, Popova said. Over the past week, the incidence has decreased by 2.5 percent. The chief sanitary doctor also expressed hope that the situation with the coronavirus in the country will stabilize. At the same time, as Popova noted, among Russians over 60, the incidence is not decreasing. The head of Rospotrebnadzor called for organizing a vaccination campaign for this category of citizens as quickly as possible.
The fact that the situation with COVID-19 in Russia remains tense was previously stated by Prime Minister Mikhail Mishustin. He noted that in a number of regions it was possible to reduce the growth rate of morbidity due to the non-working day regime.
#Russian #scientists #developed #drug #strains #COVID19